These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 29892552)
1. Secondary clonal hematologic neoplasia following successful therapy for acute promyelocytic leukemia (APL): A report of two cases and review of the literature. Gaut D; Sasine J; Schiller G Leuk Res Rep; 2018; 9():65-71. PubMed ID: 29892552 [TBL] [Abstract][Full Text] [Related]
2. [Therapy-related myeloid neoplasms after successful treatment for acute promyelocytic leukemia: a report of four cases and literature review]. Wang Z; Xu MZ; Chen YF; Xue F; Zhang L; Hu YM; Li CW; Li SZ; Wang JX; Mi YC Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1008-1014. PubMed ID: 32023731 [No Abstract] [Full Text] [Related]
3. Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia. Batzios C; Hayes LA; He SZ; Quach H; McQuilten ZK; Wall M; Campbell LJ Am J Hematol; 2009 Nov; 84(11):715-9. PubMed ID: 19806661 [TBL] [Abstract][Full Text] [Related]
4. Chromosomal abnormality of acute promyelocytic leukemia other than Imataki O; Uemura M BMC Clin Pathol; 2016; 16():16. PubMed ID: 27708545 [TBL] [Abstract][Full Text] [Related]
8. Acute Promyelocytic Leukemia: A History over 60 Years-From the Most Malignant to the most Curable Form of Acute Leukemia. Thomas X Oncol Ther; 2019 Jun; 7(1):33-65. PubMed ID: 32700196 [TBL] [Abstract][Full Text] [Related]
9. Therapy-related myelodysplastic syndrome after eradication of acute promyelocytic leukemia: cytogenetic and molecular features. Au WY; Lam CC; Ma ES; Man C; Wan T; Kwong YL Hum Pathol; 2001 Jan; 32(1):126-9. PubMed ID: 11172306 [TBL] [Abstract][Full Text] [Related]
10. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642 [TBL] [Abstract][Full Text] [Related]
11. Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. Lobe I; Rigal-Huguet F; Vekhoff A; Desablens B; Bordessoule D; Mounier C; Ferrant A; Sanz M; Fey M; Chomienne C; Chevret S; Degos L; Fenaux P; Leukemia; 2003 Aug; 17(8):1600-4. PubMed ID: 12886249 [TBL] [Abstract][Full Text] [Related]
12. Translocation (2;11)(q37;q23) in therapy-related myelodysplastic syndrome after treatment for acute promyelocytic leukemia. Snijder S; Mellink CH; van der Lelie H Cancer Genet Cytogenet; 2008 Jan; 180(2):149-52. PubMed ID: 18206542 [TBL] [Abstract][Full Text] [Related]
13. Myelodysplasia-related acute myeloid leukemia and acute promyelocytic leukemia: concomitant occurrence of two molecularly distinct diseases. Vanegas YAM; Azzouqa AM; Menke DM; Foran JM; Vishnu P Hematol Rep; 2018 Sep; 10(3):7658. PubMed ID: 30283621 [TBL] [Abstract][Full Text] [Related]
14. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript. Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486 [TBL] [Abstract][Full Text] [Related]
15. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide. Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811 [TBL] [Abstract][Full Text] [Related]
16. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2). Ogasawara T; Yasuyama M; Kawauchi K Am J Hematol; 2005 Jun; 79(2):136-41. PubMed ID: 15929101 [TBL] [Abstract][Full Text] [Related]
17. Understanding the molecular pathogenesis of acute promyelocytic leukemia. Lo-Coco F; Hasan SK Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012 [TBL] [Abstract][Full Text] [Related]
18. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells. Liu X; Chen J; Yu S; Yan L; Guo H; Dai J; Zhang W; Zhu J Cell Death Dis; 2017 May; 8(5):e2782. PubMed ID: 28492552 [TBL] [Abstract][Full Text] [Related]
19. [All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis]. Nagao R; Hosoba R; Yahagi Y; Gunji T; Uryu H; Hattori D; Momoki M; Yamazaki H Rinsho Ketsueki; 2019; 60(10):1431-1435. PubMed ID: 31695003 [TBL] [Abstract][Full Text] [Related]
20. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Zheng X; Seshire A; RĂ¼ster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]